Journal
HUMAN VACCINES & IMMUNOTHERAPEUTICS
Volume 8, Issue 11, Pages 1585-1594Publisher
TAYLOR & FRANCIS INC
DOI: 10.4161/hv.21872
Keywords
Staphylococcus aureus vaccine; vaccine development; immune evasion; clinical trial; virulence factor
Categories
Funding
- Pfizer
Ask authors/readers for more resources
Staphylococcus aureus is a major cause of healthcare-associated infections and is responsible for a substantial burden of disease in hospitalized patients. Despite increasingly rigorous infection control guidelines, the prevalence and corresponding negative impact of S. aureus infections remain considerable. Difficulties in controlling S. aureus infections as well as the associated treatment costs are exacerbated by increasing rates of resistance to available antibiotics. Despite ongoing efforts over the past 20 years, no licensed S. aureus vaccine is currently available. However, learnings from past clinical failures of vaccine candidates and a better understanding of the immunopathology of S. aureus colonization and infection have aided in the design of new vaccine candidates based on multiple important bacterial pathogenesis mechanisms. This review outlines important considerations in designing a vaccine for the prevention of S. aureus disease in healthcare settings.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available